Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
UTC Therapeutics Inc.
Suzhou Genhouse Bio Co., Ltd.
Shanghai YingLi Pharmaceutical Co. Ltd.
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
NGM Biopharmaceuticals, Inc
Wellmarker Bio
Suzhou Immunofoco Biotechnology Co., Ltd
Chongqing Precision Biotech Co., Ltd
Cedars-Sinai Medical Center
Sheba Medical Center
Rise Biopharmaceuticals, Inc.
Minneamrita Therapeutics LLC
Shanghai YingLi Pharmaceutical Co. Ltd.
Peking University
Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.
Impact Therapeutics, Inc.
Genzada Pharmaceuticals USA, Inc.
Amsterdam UMC, location VUmc
Minneamrita Therapeutics LLC
Provectus Pharmaceuticals
Wellmarker Bio
Betta Pharmaceuticals Co., Ltd.
Samsung Medical Center
Betta Pharmaceuticals Co., Ltd.
Zhongnan Hospital
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Peking University Cancer Hospital & Institute
Benaroya Research Institute
Jiangsu HengRui Medicine Co., Ltd.
Loyola University
Critical Outcome Technologies Inc.
Placon Therapeutics
Ludwig-Maximilians - University of Munich
Atlantic Health System
Threshold Pharmaceuticals
Tianjin Medical University Cancer Institute and Hospital
Southwest Hospital, China
Wakayama Medical University
e-Therapeutics PLC
Shanghai GeneChem Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University
US Oncology Research
Chinese PLA General Hospital
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co., Ltd.
Ochsner Health System
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fukushima Medical University
University of Belgrade